title: Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
abstract: This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated cohort treated with ferric carboxymaltose (FCM) has been reported earlier.
  
  
  
  Data of patients with a solid tumour or haematological malignancy who have received IS or an RBC transfusion during 2010 from 3 months prior (M-3) to 3 months post first treatment (M+3) were analysed.
  
  
  
  Data from 46 patients who had received IS (400 mg median total iron dose) and 357 patients who had received RBC transfusions as first treatment (baseline) were included. Median haemoglobin levels improved from 9.9 g/dL (interquartile range 9.2; 11.0 g/dL) at baseline to 12.4 g/dL (11.4; 13.1 g/dL) at M+3in IS-treated patients and from 8.2 g/dL (7.8; 8.8 g/dL) at baseline to 10.1 g/dL (8.8; 11.1 g/dL) in transfused patients. An erythropoiesis-stimulating agent was given to 54.3 and 28.9% of patients in the IS and the RBC transfusion groups, respectively, resulting in slightly better mean haemoglobin increase in both groups (2.4 vs 1.5 g/dL and 2.0 vs 1.6 g/dL, respectively). No severe nor serious adverse reaction and no hypersensitivity reactions were reported.
  
  
  
  Both IS and RBC transfusions effectively increased Hb levels in patients with cancer. IS was safe and well tolerated in this population. Considering prior reported results with FCM, using FCM may reduce ESA dose requirements and the required number of infusions.
authors.affiliation: Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France. e.luporsi@nancy.unicancer.fr.|Oncologue médical, Biostatisticien, Généticien, PMSI Oncomed, Coordination réseau lorrain GENECAL, Institut de Cancérologie de Lorraine Alexis Vautrin, Avenue de Bourgogne, F 54511, Vandoeuvre-Les-Nancy, France. e.luporsi@nancy.unicancer.fr.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Luporsi
authors.affiliation: American Hospital of Paris, Neuilly-sur-Seine, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Toledano
authors.affiliation: Centre d'Oncologie de Gentilly, Nancy, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Spaeth
authors.affiliation: Hôpital Européen Georges-Pompidou, Paris, France.
authors.forename: Florian
authors.initials: F
authors.lastname: Scotté
authors.affiliation: Hôpital Saint Louis, Paris, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Espié
authors.affiliation: ICTA, Fontaine-les-Dijon, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Perot
authors.affiliation: Vifor Pharma, Cedex, Neuilly-sur-Seine, France.
authors.forename: Ladan
authors.initials: L
authors.lastname: Duvillié
authors.affiliation: Vifor Pharma, Cedex, Neuilly-sur-Seine, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Pithois Merli
authors.affiliation: Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.
authors.forename: Roland
authors.initials: R
authors.lastname: Bugat
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D017707:Erythrocyte Transfusion / Q000379:methods*; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000378:metabolism; D005602:France; D005937:Glucaric Acid / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008320:Maltose / Q000008:administration & dosage / Q000031:analogs & derivatives; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy; D012189:Retrospective Studies
chemical_list: D005290:Ferric Compounds; D006454:Hemoglobins; C522335:ferric carboxymaltose; D008320:Maltose; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid
keywords: Intravenous iron - Iron sucrose; Patients; RBC transfusion